Objectives To predict axillary node residual disease in women treated for node-positive breast cancer (BC) by neoadjuvant therapy (NAT), using breast BI-RADS MRI features and axillary ultrasound at baseline. Material and methods In this single-center, retrospective study, women with node-positive BC who underwent NAT between 2016 and 2021 were included. Pre-treatment axillary US and breast MRIs were evaluated using the BI-RADS lexicon and T2 features, including Breast Edema Score. Univariate and multivariate logistic regression analyses were conducted for the prediction of axillary residual disease (ARD). A multivariable model based on logistic regression was trained and evaluated on randomly split train and test sets (7:3 ratio). Results Out of the 141 women, 41% had post-NAT ARD. Axillary metastasis was independently associated with luminal subtype (odds ratio (OR), 25.5; p < 0.001), anterior tumor location (OR, 14.1; p = 0.008), and cortical thickening ≥ 7 mm (OR, 6.09; p = 0.002). Intratumoral T2 high signal intensity was protective (OR, 0.16; p = 0.006), while Ki67 had a marginal association (p = 0.064). In the training and test sets, the model, which is available online, achieved AUCs of 0.860 (95% CI: 0.783–0.936) and 0.843 (95% CI: 0.714–0.971), respectively. Anterior depth location and cortical thickening greater than 7 mm were also independently associated with post-NAT axillary burden. Conclusion Adjusting for BC subtype and KI-67 index, the anterior third location of BC, a cortical thickness greater than 7 mm, and the absence of intratumoral T2 hyperintensity is predictive of ARD after NAT. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> What baseline imaging-based predictive models can identify patients at risk of persistent nodal disease after neoadjuvant therapy? <Emphasis Type="BoldItalic">Findings</Emphasis> Baseline US cortical thickness superior to 7 mm, anterior tumor location, and absence of an intratumoral high signal on T2-weighted MRI predict residual axillary disease. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> Our predictive model, available online at: <a href="http://litoic.shinyapps.io/LNPred_Apps">litoic.shinyapps.io/LNPred_Apps</a>, including breast cancer subtype, Ki-67 index level, breast cancer location, intratumoral signal intensity on T2WI, and initial lymph node thickness, could guide post-NAT axillary management. Graphical Abstract

Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound

期刊论文
出版模式：

开放获取
发表日期：

2025年2月8日

查看全文

Caroline Malhaire,
Ozgun Umay,
Vincent Cockenpot,
Fatine Selhane,
Toulsie Ramtohul,
Fabien Reyal,
Jean-Yves Pierga,
Emanuella Romano,
Anne Vincent-Salomon,
Youlia Kirova,
Enora Laas,
Hervé J. Brisse,
Frédérique Frouin

摘要

Objectives

To predict axillary node residual disease in women treated for node-positive breast cancer (BC) by neoadjuvant therapy (NAT), using breast BI-RADS MRI features and axillary ultrasound at baseline.

Material and methods

In this single-center, retrospective study, women with node-positive BC who underwent NAT between 2016 and 2021 were included. Pre-treatment axillary US and breast MRIs were evaluated using the BI-RADS lexicon and T2 features, including Breast Edema Score. Univariate and multivariate logistic regression analyses were conducted for the prediction of axillary residual disease (ARD). A multivariable model based on logistic regression was trained and evaluated on randomly split train and test sets (7:3 ratio).

Results

Out of the 141 women, 41% had post-NAT ARD. Axillary metastasis was independently associated with luminal subtype (odds ratio (OR), 25.5; p < 0.001), anterior tumor location (OR, 14.1; p = 0.008), and cortical thickening ≥ 7 mm (OR, 6.09; p = 0.002). Intratumoral T2 high signal intensity was protective (OR, 0.16; p = 0.006), while Ki67 had a marginal association (p = 0.064). In the training and test sets, the model, which is available online, achieved AUCs of 0.860 (95% CI: 0.783–0.936) and 0.843 (95% CI: 0.714–0.971), respectively. Anterior depth location and cortical thickening greater than 7 mm were also independently associated with post-NAT axillary burden.

Conclusion

Adjusting for BC subtype and KI-67 index, the anterior third location of BC, a cortical thickness greater than 7 mm, and the absence of intratumoral T2 hyperintensity is predictive of ARD after NAT.

Key Points

Question What baseline imaging-based predictive models can identify patients at risk of persistent nodal disease after neoadjuvant therapy?

Findings Baseline US cortical thickness superior to 7 mm, anterior tumor location, and absence of an intratumoral high signal on T2-weighted MRI predict residual axillary disease.

Clinical relevance Our predictive model, available online at: litoic.shinyapps.io/LNPred_Apps, including breast cancer subtype, Ki-67 index level, breast cancer location, intratumoral signal intensity on T2WI, and initial lymph node thickness, could guide post-NAT axillary management.

Graphical Abstract